{{Infobox drug
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 476995047
| drug_name =
| IUPAC_name = (4''E'')-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
| image = Mycophenolicacid.svg
| width = 200
| image2 = Mycophenolic acid ball-and-stick.png
<!--Clinical data-->
| pronounce = {{IPAc-en|ˌ|m|aɪ|k|oʊ|f|ᵻ|ˈ|n|ɒ|l|ɪ|k}}
| tradename = CellCept, Myfortic
| Drugs.com = {{drugs.com|MTM|mycophenolic-acid}}
| MedlinePlus = a601081
| licence_EU = Cellcept
| licence_US = mycophenol
| pregnancy_AU = D
| pregnancy_US = D
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = Oral,<br/>[[靜脈注射|靜脈注射]]<ref name="Austria-Codex">{{cite book|title=Austria-Codex|editor=Jasek, W|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2007|edition=62nd|pages=1484–95|isbn=978-3-85200-181-4|language=de}}</ref>
<!--Pharmacokinetic data-->
| bioavailability = 72% (sodium),<br/>94% (mofetil)<ref name = TGA>{{cite web|title=CellCept|work=TGA eBusiness Services|publisher=Roche Products Pty Limited|date=13 December 2012|accessdate=25 February 2014|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-03448-3|format=PDF}}</ref>
| protein_bound = 82–97%<ref name = TGA/>
| metabolism = Hepatic<ref name = TGA/>
| elimination_half-life = 17.9±6.5 hours<ref name = TGA/>
| excretion = Urine (93%),<br/>faeces (6%)<ref name = TGA/>
<!--Identifiers-->
| IUPHAR_ligand = 6832
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 24280-93-1
| ATC_prefix = L04
| ATC_suffix = AA06
| PubChem = 446541
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01024
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 393865
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = HU9DX48N0T
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D05096
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 168396
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 866
<!--Chemical data-->
| C=17 | H=20 | O=6
| molecular_weight = 320.34 g/mol
| smiles = O=C1OCc2c1c(O)c(c(OC)c2C)C\C=C(/C)CCC(=O)O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = HPNSFSBZBAHARI-RUDMXATFSA-N
}}

{{Infobox drug
| drug_name= Mycophenolate mofetil
| Verifiedfields = changed
| verifiedrevid = 476999346
| image = Mycophenolate mofetil2DACS.svg
| width = 250px
| image2=Mycophenolate mofetil ball-and-stick.png
| IUPAC_name = 2-Morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
<!--Clinical data-->
| tradename = CellCept
| Drugs.com = {{drugs.com|monograph|mycophenolate-mofetil}}
| licence_EU = CellCept
| licence_US = Mycophenolate_mofetil
| legal_status =
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 128794-94-5
| ATC_prefix = L04
| ATC_suffix = AA06
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 8764
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = C07908
| PubChem=5281078
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1456
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00688
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4444535
<!--Chemical data-->
| C=23 | H=31 | N=1 | O=7
| molecular_weight=433.49474 g/mol
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = RTGDFNSFWBGLEC-SYZQJQIISA-N
| smiles=CC1=C(C(=C(C2=C1COC2=O)O)CC=C(C)CCC(=O)OCCN3CCOCC3)OC
}}

'''黴酚酸'''（英文：Mycophenolic acid 或 mycophenolate），為[[器官移植|器官移植]]手術使用來預防排斥作用的[[免疫抑制药物|免疫抑制藥物]]。它抑制[[T细胞|T細胞]]與[[B细胞|B細胞]]生長所需的酵素。早期黴酚酸是以黴酚酸酯的[[前体药物|前體藥物]]之型態來販售，以提升它的[[生物利用度|生物利用度]]。 近年來，它也以黴酚酸鈉（睦體康<ref>{{Cite web|url=http://www.cth.org.tw/?aid=606&pid=0&page_name=detail&iid=290|title=B023737100 {{!}} 藥品資訊 {{!}} 就醫指南 {{!}} 天主教耕莘醫療財團法人耕莘醫院|accessdate=2017-05-13|work=www.cth.org.tw|language=zh-TW}}</ref>）的形式販售，而黴酚酸酯在市面上也可以買到（山喜多<ref>{{Cite web|url=http://www.roche.com.tw/home/products/products01/cellcept.html|title=CellCept®山喜多®|accessdate=2017-05-13|work=www.roche.com.tw|language=zh-TW}}</ref>）。 

黴酚酸原本是由義大利醫學家[[巴托羅密歐·高西歐|巴托羅密歐‧高西歐]]在1893年發現的抗生素，也是第一個人工合成與純化到結晶型態的抗生素；但是它卻被世人所遺忘，直到1912年美國科學家阿爾斯柏格與布萊克重新合成並將之命名為黴酚酸，才又得到注意。它是一個廣效性的藥物，可用於抗病毒、抗真菌、抗癌以及抗銀屑病<ref name=silverman>{{cite journal|last1=Silverman Kitchin|first1=Jennifer E.|last2=Pomeranz|first2=Miriam Keltz|last3=Pak|first3=Grace|last4=Washenik|first4=Ken|last5=Shupack|first5=Jerome L.|title=Rediscovering mycophenolic acid: A review of its mechanism, side effects, and potential uses|journal=Journal of the American Academy of Dermatology|year=1997|volume=37|issue=3|pages=445–449|doi=10.1016/S0190-9622(97)70147-6}}</ref>。山喜多是由南美洲遺傳學家{{Le|安東尼‧艾力森|Anthony Clifford Allison}}與他的妻子艾爾西‧悠桂（Elsie M. Eugui）開發出來，並於1995年5月3日通過[[美国食品药品监督管理局|美國食品藥品監督管理局]]許可用於腎臟移植<ref name=fda>{{cite web|title=Risk Evaluation and Mitigation Strategy (REMS) Under Review for CellCept and Myfortic|url=http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm148735.htm|publisher=U.S. Food and Drug Administration|accessdate=23 July 2014}}</ref>。

==醫療用途==
黴酚酸主要用於預防[[器官移植|器官移植]]排斥。對於預防成人器官移植排斥與預防兩歲以上兒童[[腎臟移植|腎臟移植]]排斥，可用黴酚酸酯；而黴酚酸鈉則可用於預防成人與兩歲以上腎臟、[[肝臟|肝臟]]、[[心臟|心臟]]、心肺、肺臟移植排斥<ref name="AMH2006">Rossi S, editor. {{tsl|en|Australian Medicines Handbook||Australian Medicines Handbook}} 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3{{Page needed|date=September 2010}}</ref>，也可以與其他藥物並用來治療腹膜後纖維化<ref>{{cite book|last1=editor|first1=Mark Harber,|title=Practical nephrology|date=2014|isbn=9781447155478|page=449|url=https://books.google.co.jp/books?id=6GQgBAAAQBAJ&pg=PA449}}</ref>。

除了用來預防器官移植受贈者發生急性排斥作用以外，近年來黴酚酸酯用來治療如[[貝賽特氏症|貝賽特氏症]]、尋常型天皰瘡、頑固性不全[[紅斑性狼瘡|系統性紅斑狼瘡]]、免疫球蛋白A腎病、小血管炎、[[銀屑病|銀屑病]]等[[自體免疫性疾病|自體免疫疾病]]的案例也愈來愈多<ref name="Moore">{{Cite journal|vauthors=Moore RA, Derry S |title=Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis |journal={{tsl|en|Arthritis Research & Therapy||Arthritis Research & Therapy}} |volume=8 |issue=6 |pages=R182 |year=2006 |pmid=17163990 |pmc=1794528 |doi=10.1186/ar2093}}</ref><ref>Boehm I et al. Chilblain lupus erythematosus Hutchinson: successful treatment with mycophenolate mofetil. Arch Dermatol 2001;137:235 – 236      http://archderm.jamanetwork.com/article.aspx?articleid=478189</ref>。

在狼瘡性腎炎的治療上，因為相比於[[环磷酰胺|環磷酰胺]]丸劑，黴酚酸少了副作用（骨髓抑制、不育、惡性化）<ref name="DCruz">{{Cite journal|vauthors=D'Cruz DP, Khamashta MA, Hughes GR |title=Systemic lupus erythematosus |journal=Lancet |volume=369 |issue=9561 |pages=587–96 |date=February 2007 |pmid=17307106 |doi=10.1016/S0140-6736(07)60279-7}}</ref><ref name="Moore" />且病人反應較佳，因此採用黴酚酸治療狼瘡性腎炎有增加的趨勢。在持續的治療上，黴酚酸的表現也較環磷酰胺為佳<ref name="DCruz" />。 沃爾什等人甚至認為在病人的沒有喪失腎功能的情況下，應該先使用黴酚酸來治療狼瘡性腎炎<ref name="Walsh">{{Cite journal|vauthors=Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgarn BR |title=Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis |journal=Clinical Journal of the American Society of Nephrology |volume=2 |issue=5 |pages=968–75 |date=September 2007 |pmid=17702723 |doi=10.2215/CJN.01200307}}</ref>。

===與其他藥物比較===
與[[硫唑嘌呤|硫唑嘌呤]]相比，黴酚酸比較容易造成腹瀉<ref>{{Cite journal|vauthors=Knight SR, Russell NK, Barcena L, Morris PJ |title=Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review |journal=Transplantation |volume=87 |issue=6 |pages=785–94 |date=March 2009 |pmid=19300178 |doi=10.1097/TP.0b013e3181952623}}</ref>，而且價格是硫唑嘌呤的十五倍<ref>{{Cite journal |vauthors=Remuzzi G, Lesti M, Gotti E, etal |title=Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial |journal=Lancet |volume=364 |issue=9433 |pages=503–12 |year=2004 |pmid=15302193 |doi=10.1016/S0140-6736(04)16808-6}}</ref>；因此到底要不要使用黴酚酸來取代硫唑嘌呤尚無結論。

==參考文獻==
{{Reflist|colwidth=30em}}

{{Immunosuppressants}}

{{DEFAULTSORT:Mycophenolic Acid}}
[[Category:内酯|Category:内酯]]
[[Category:吗啉|Category:吗啉]]
[[Category:异苯并呋喃|Category:异苯并呋喃]]
[[Category:免疫抑制剂|Category:免疫抑制剂]]
[[Category:羧酸衍生物|Category:羧酸衍生物]]
[[Category:酚酸|Category:酚酸]]
[[Category:酚脂类|Category:酚脂类]]